vs

Side-by-side financial comparison of NexPoint Residential Trust, Inc. (NXRT) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

NexPoint Residential Trust, Inc. is the larger business by last-quarter revenue ($62.1M vs $37.2M, roughly 1.7× Organogenesis Holdings Inc.). On growth, NexPoint Residential Trust, Inc. posted the faster year-over-year revenue change (-2.7% vs -57.1%). Over the past eight quarters, NexPoint Residential Trust, Inc.'s revenue compounded faster (-4.1% CAGR vs -46.5%).

NexPoint Residential Trust, Inc. is a publicly traded real estate investment trust focused on acquiring, renovating, and operating multifamily residential properties primarily across high-growth Sun Belt markets in the United States. Its portfolio consists mainly of affordable and mid-tier apartment communities, targeting steady rental income growth and long-term asset value appreciation for investors.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

NXRT vs ORGO — Head-to-Head

Bigger by revenue
NXRT
NXRT
1.7× larger
NXRT
$62.1M
$37.2M
ORGO
Growing faster (revenue YoY)
NXRT
NXRT
+54.4% gap
NXRT
-2.7%
-57.1%
ORGO
Faster 2-yr revenue CAGR
NXRT
NXRT
Annualised
NXRT
-4.1%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
NXRT
NXRT
ORGO
ORGO
Revenue
$62.1M
$37.2M
Net Profit
Gross Margin
30.8%
Operating Margin
8.4%
-185.1%
Net Margin
Revenue YoY
-2.7%
-57.1%
Net Profit YoY
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NXRT
NXRT
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$62.1M
$225.6M
Q3 25
$62.8M
$150.9M
Q2 25
$63.1M
$101.0M
Q1 25
$63.2M
$86.7M
Q4 24
$63.8M
$126.7M
Q3 24
$64.1M
$115.2M
Q2 24
$64.2M
$130.2M
Net Profit
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
$43.7M
Q3 25
$-7.8M
$21.6M
Q2 25
$-7.0M
$-9.4M
Q1 25
$-6.9M
$-18.8M
Q4 24
$7.7M
Q3 24
$-8.9M
$12.3M
Q2 24
$10.6M
$-17.0M
Gross Margin
NXRT
NXRT
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
NXRT
NXRT
ORGO
ORGO
Q1 26
-185.1%
Q4 25
8.4%
28.1%
Q3 25
11.8%
13.7%
Q2 25
12.5%
-12.5%
Q1 25
11.7%
-30.9%
Q4 24
18.0%
8.1%
Q3 24
8.7%
5.4%
Q2 24
39.7%
-10.7%
Net Margin
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
19.4%
Q3 25
-12.4%
14.3%
Q2 25
-11.1%
-9.3%
Q1 25
-10.9%
-21.7%
Q4 24
6.1%
Q3 24
-13.8%
10.7%
Q2 24
16.5%
-13.1%
EPS (diluted)
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
$0.31
Q3 25
$-0.31
$0.11
Q2 25
$-0.28
$-0.10
Q1 25
$-0.27
$-0.17
Q4 24
$0.05
Q3 24
$-0.35
$0.09
Q2 24
$0.40
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NXRT
NXRT
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$13.7M
$91.4M
Total DebtLower is stronger
$1.6B
Stockholders' EquityBook value
$295.5M
Total Assets
$1.9B
$520.0M
Debt / EquityLower = less leverage
5.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NXRT
NXRT
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$13.7M
$93.7M
Q3 25
$10.8M
$63.7M
Q2 25
$13.6M
$73.1M
Q1 25
$23.7M
$110.0M
Q4 24
$23.1M
$135.6M
Q3 24
$17.4M
$94.3M
Q2 24
$21.3M
$89.9M
Total Debt
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
$1.6B
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
$295.5M
$300.1M
Q3 25
$322.9M
$255.1M
Q2 25
$347.9M
$233.2M
Q1 25
$379.9M
$242.9M
Q4 24
$410.4M
$262.9M
Q3 24
$447.1M
$278.5M
Q2 24
$491.1M
$263.5M
Total Assets
NXRT
NXRT
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$1.9B
$598.7M
Q3 25
$1.8B
$509.8M
Q2 25
$1.9B
$461.1M
Q1 25
$1.9B
$467.4M
Q4 24
$1.9B
$497.9M
Q3 24
$2.0B
$446.3M
Q2 24
$2.0B
$443.2M
Debt / Equity
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
5.39×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NXRT
NXRT
ORGO
ORGO
Operating Cash FlowLast quarter
$83.6M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
$83.6M
$39.4M
Q3 25
$29.3M
$3.1M
Q2 25
$19.9M
$-32.9M
Q1 25
$28.3M
$-19.9M
Q4 24
$73.6M
$10.9M
Q3 24
$27.8M
$8.7M
Q2 24
$19.7M
$4.7M
Free Cash Flow
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
NXRT
NXRT
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
0.14×
Q2 25
Q1 25
Q4 24
1.43×
Q3 24
0.71×
Q2 24
1.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons